Sign in

    Emily • Stifel

    Emily Mendelson is an Associate at The Halifax Group who previously served as an Investment Banking Analyst at Stifel, supporting M&A advisory services across the Environmental Services and Business Services sectors. At Stifel, she contributed to numerous sell-side and buy-side transactions for clients in these industries, demonstrating strong analytical acumen and transaction execution skills during her tenure. She began her career at Stifel in Baltimore before joining Halifax in 2024, following the completion of her B.S.B.A. in Finance from the University of Richmond’s Robins School of Business. Emily’s credentials are grounded in her rigorous finance education and hands-on deal experience in investment banking.

    Emily's questions to Alector Inc (ALEC) leadership

    Emily's questions to Alector Inc (ALEC) leadership • Q2 2025

    Question

    Emily from Stifel asked about the potential for regulatory approval if the INFRONT3 trial successfully meets its progranulin endpoint but shows more equivocal clinical data. She also asked for confirmation that the FDA remains aligned on the trial's sample size.

    Answer

    CMO Giacomo Salvadore stated that while the company is pursuing full approval, they would be open to dialogue with regulators based on the totality of evidence, citing the approval of tofersen in SOD1 ALS as a precedent for biomarker-based approvals. He also confirmed alignment with the FDA on the sample size following a 2023 blinded re-estimation.

    Ask Fintool Equity Research AI